Can FDA's Breakthrough Program Finally Midwife Gene Therapy?
The often-troubled field is showing promise, and the extra resources that breakthrough designation will bring to two candidates could be what gene therapy needs to move from the theoretical to the marketable.
You may also be interested in...
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.
A death was reported in the company's early-stage gene therapy trial. It has not been determined yet whether the death was related to the drug and what the next steps for the company are.
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.